Comparative Effectiveness of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in Older Nursing Home Residents After Myocardial Infarction: A Retrospective Cohort Study

Overview

Journal Drugs Aging

Specialties Geriatrics
Pharmacology

Date 2020 Aug 19

PMID 32808250

Authors

Andrew R Zullo

Melissa R Riester

Sebhat Erqou

Wen-Chih Wu

James L Rudolph

Michael A Steinman

Affiliations

Soon will be listed here.

Abstract

Background: Evidence regarding differences in outcomes between angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) among older nursing home (NH) residents after acute myocardial infarction (AMI) is limited.

Objectives: The purpose of our study was to estimate the post-AMI effects of ARBs versus ACEIs on mortality, rehospitalization, and functional decline outcomes in this important population.

Methods: This retrospective cohort study used national Medicare claims linked to Minimum Data Set assessments. The study population included individuals aged ≥ 65 years who resided in a US NH ≥ 30 days, were hospitalized for AMI between May 2007 and March 2010, and returned to the NH. We compared 90-day mortality, rehospitalization, and functional decline outcomes between ARB and ACEI users with inverse-probability-of-treatment-weighted binomial and multinomial logistic regression models.

Results: Of the 2765 NH residents, 270 (9.8%) used ARBs and 2495 (90.2%) used ACEIs. The mean age of ARB versus ACEI users was 82.3 versus 82.7 years, respectively. No marked differences existed between ARB and ACEI users for mortality [odds ratio (OR) 1.18; 95% confidence interval (CI) 0.78-1.79], rehospitalization (OR 1.22; 95% CI 0.90-1.65), or functional decline (OR 1.23; 95% CI 0.88-1.74). In subgroup analyses, ARBs were associated with increased mortality and rehospitalization in individuals with moderate to severe cognitive impairment and with increased rehospitalization in those aged < 85 years.

Conclusions: Our findings align with prior data and suggest that clinicians can prescribe either ARBs or ACEIs post-AMI for secondary prevention in NH residents, although the subgroup findings merit further scrutiny and replication. Providers should consider factors such as patient preferences, class-specific adverse events, and costs when prescribing.

References

Carpenter G, Hastie C, Morris J, Fries B, Ankri J . Measuring change in activities of daily living in nursing home residents with moderate to severe cognitive impairment. BMC Geriatr. 2006; 6:7. PMC: 1522014. DOI: 10.1186/1471-2318-6-7. View

VanderWeele T . On the distinction between interaction and effect modification. Epidemiology. 2009; 20(6):863-71. DOI: 10.1097/EDE.0b013e3181ba333c. View

Stuhec M, Keuschler J, Serra-Mestres J, Isetta M . Effects of different antihypertensive medication groups on cognitive function in older patients: A systematic review. Eur Psychiatry. 2017; 46:1-15. DOI: 10.1016/j.eurpsy.2017.07.015. View

Huitfeldt A, Hernan M, Kalager M, Robins J . Comparative Effectiveness Research Using Observational Data: Active Comparators to Emulate Target Trials with Inactive Comparators. EGEMS (Wash DC). 2016; 4(1):1234. PMC: 5108633. DOI: 10.13063/2327-9214.1234. View

Zullo A, Ofori-Asenso R, Wood M, Zuern A, Lee Y, Wu W . Effects of Statins for Secondary Prevention on Functioning and Other Outcomes Among Nursing Home Residents. J Am Med Dir Assoc. 2020; 21(4):500-507.e8. PMC: 7127965. DOI: 10.1016/j.jamda.2020.01.102. View

Morris J, Fries B, Morris S . Scaling ADLs within the MDS. J Gerontol A Biol Sci Med Sci. 2000; 54(11):M546-53. DOI: 10.1093/gerona/54.11.m546. View

Zhuang S, Wang H, Li J, Wang H, Wang X, Xing C . Renin-angiotensin system blockade use and risks of cognitive decline and dementia: A meta-analysis. Neurosci Lett. 2016; 624:53-61. DOI: 10.1016/j.neulet.2016.05.003. View

Donohue J, Morden N, Gellad W, Bynum J, Zhou W, Hanlon J . Sources of regional variation in Medicare Part D drug spending. N Engl J Med. 2012; 366(6):530-8. PMC: 3285245. DOI: 10.1056/NEJMsa1104816. View

Zullo A, Lee Y, Daiello L, Mor V, Boscardin W, Dore D . Beta-Blocker Use in U.S. Nursing Home Residents After Myocardial Infarction: A National Study. J Am Geriatr Soc. 2016; 65(4):754-762. PMC: 5397324. DOI: 10.1111/jgs.14671. View

10.

Antman E, Hand M, Armstrong P, Bates E, Green L, Halasyamani L . 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2008; 51(2):210-47. DOI: 10.1016/j.jacc.2007.10.001. View

11.

Rockwood K, Mitnitski A . Frailty defined by deficit accumulation and geriatric medicine defined by frailty. Clin Geriatr Med. 2010; 27(1):17-26. DOI: 10.1016/j.cger.2010.08.008. View

12.

Fleg J, Forman D, Berra K, Bittner V, Blumenthal J, Chen M . Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association. Circulation. 2013; 128(22):2422-46. PMC: 4171129. DOI: 10.1161/01.cir.0000436752.99896.22. View

13.

. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993; 342(8875):821-8. View

14.

Pfeffer M, Braunwald E, Moye L, Basta L, Brown Jr E, Cuddy T . Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992; 327(10):669-77. DOI: 10.1056/NEJM199209033271001. View

15.

Krishnaswami A, Steinman M, Goyal P, Zullo A, Anderson T, Birtcher K . Deprescribing in Older Adults With Cardiovascular Disease. J Am Coll Cardiol. 2019; 73(20):2584-2595. PMC: 6724706. DOI: 10.1016/j.jacc.2019.03.467. View

16.

Zullo A, Mogul A, Corsi K, Shah N, Lee S, Rudolph J . Association Between Secondary Prevention Medication Use and Outcomes in Frail Older Adults After Acute Myocardial Infarction. Circ Cardiovasc Qual Outcomes. 2019; 12(4):e004942. PMC: 6481629. DOI: 10.1161/CIRCOUTCOMES.118.004942. View

17.

Barthold D, Joyce G, Wharton W, Kehoe P, Zissimopoulos J . The association of multiple anti-hypertensive medication classes with Alzheimer's disease incidence across sex, race, and ethnicity. PLoS One. 2018; 13(11):e0206705. PMC: 6211717. DOI: 10.1371/journal.pone.0206705. View

18.

Steinman M, Zullo A, Lee Y, Daiello L, Boscardin W, Dore D . Association of β-Blockers With Functional Outcomes, Death, and Rehospitalization in Older Nursing Home Residents After Acute Myocardial Infarction. JAMA Intern Med. 2016; 177(2):254-262. PMC: 5318299. DOI: 10.1001/jamainternmed.2016.7701. View

19.

Danaei G, Garcia Rodriguez L, Cantero O, Logan R, Hernan M . Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease. Stat Methods Med Res. 2011; 22(1):70-96. PMC: 3613145. DOI: 10.1177/0962280211403603. View

20.

Velazquez E, Pfeffer M, McMurray J, Maggioni A, Rouleau J, Van de Werf F . VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. Eur J Heart Fail. 2003; 5(4):537-44. DOI: 10.1016/s1388-9842(03)00112-0. View